Purpose The main objective of this present study was the investigation of potential novel transdermal patch technology (TEPI�®)\ndelivering ibuprofen as the active pharmaceutical ingredient (API) using a novel poly(ether-urethane)-silicone crosslinked\npressure-sensitive adhesive (PSA) as the drug reservoir in a solvent-free manufacturing process.\nMethods The patch was synthesized utilizing the hot-melt crosslinking technique without the addition of solvents at 80 �°C in\n100% relative humidity. Dissolution and permeation studies performed utilizing diffusion cells and subsequentlyHPLC validated\nmethods were employed to determine the API content in the acceptor solution. Accelerated stability studies were also performed\nat 40 �°C and 70%relative humidity. The adhesive performance of the fabricated patch was evaluated utilizing loop tack adhesion\ntests.\nResults In vitro permeation experiments across both Strat-M�® and human skin demonstrated that ibuprofen can easily be\nreleased from the adhesive matrix and penetrate through the studied membrane. A comparison on the permeation rates of the\nAPI across the two membranes indicated that there is not a strong correlation between the obtained data. The presence of\nchemical enhancers facilitated an increased flux of the API higher than observed in the basic formulation. Initial stability studies\nof the optimized formulation showed no degradation with respect to the drug content. Adhesion studies were also performed\nindicating higher values when compared with commercially available products.\nConclusions The present study demonstrated the fabrication of an ibuprofen patch utilizing a versatile, solvent-free drug delivery\nplatform. Upon optimization of the final system, the resulting patch offers many advantages compared to commercially available\nformulations including high drug loading (up to 25 wt%), good adhesion, and painless removal leaving no residues on the skin.\nThis PSA offers many advantages over existing adhesive technology.
Loading....